WhiteSwell is a science-driven company dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits.  The company is pioneering a minimally invasive catheter-based approach designed to more efficiently remove excess interstitial fluid in patients with ADHF by enhancing the natural fluid removal process of the lymphatic system. For more information visit www.whiteswell.com.

Health Care

Life Sciences

Medical Devices

WhiteSwell

Eamon Brady

Michael Jonas

Alva Bradley

George Bakris

Suzanne Hansel

Joann Lindenfeld

Ronan Keating

Martin Keegan

Jill Amstutz

Ann Marie Cannon

Andrew Levin

Andrew Farquharson

Seán Mac Réamoinn

The Research and Development team at WhiteSwell drives innovation to enhance the treatment of acute decompensated heart failure (ADHF). The team, led by experienced professionals such as the VP of Research & Development and Senior R&D Engineers, focuses on pioneering and refining a minimally invasive, catheter-based approach for efficient interstitial fluid removal. They work collaboratively to enhance the efficacy and safety of the technology, ensuring it meets clinical and regulatory standards.

Research and Development

Leadership Team

Medical Professionals

Research and Development

About

Team members

Other teams at WhiteSwell

Leadership Team

Medical Professionals